Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4): 529-38.
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156(4): 271-8.
Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res 2015; 119: 89-96.
Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction 2004; 99(9): 1167-75.
Walley AY, White MC, Kushel MB, Song YS, Tulsky JP. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005; 28(2): 181-7.
Eskandarieh S, Nikfarjam A, Tarjoman T, Nasehi A, Jafari F, Saberi-Zafarghandi MB. Descriptive aspects of injection drug users in Iranâs national harm reduction program by methadone maintenance treatment. Iran J Public Health 2013; 42(6): 588-93.
Alam-Mehrjerdi Z, Abdollahi M, Higgs P, Dolan K. Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country. Asian J Psychiatr 2015; 16: 78-83.
Mehrjerdi ZA, Abarashi Z, Noroozi A, Arshad L, Zarghami M. Correlates of shared methamphetamine injection among methamphetamine-injecting treatment seekers: The first report from Iran. Int J STD AIDS 2014; 25(6): 420-7.
Alam-mehrjerdi Z, Noori R, Dolan K. Opioid use, treatment and harm reduction services: The first report from the Persian Gulf region. J Subst Use 2016; 21(2): 217-23.
Alam-Mehrjerdi Z, Moradi A, Xu F, Zarghami M, Salehi-Fadardi J, Dolan K. Willingness to receive treatment for hepatitis c among injecting drug users on methadone program: Implications for education and treatment. Addict Health 2016; 8(2): 90-7.
Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002; 67(2): 117-23.
Clark PJ, Muir AJ. Overcoming barriers to care for hepatitis C. N Engl J Med 2012; 366(26): 2436-8.
Strauss A, Corbin J. Basics of qualitative research: Grounded theory procedures and techniques. SAGE Publications: Thousand Oaks, CA; 1990.
Pope C, Mays N. Reaching the parts other methods cannot reach: An introduction to qualitative methods in health and health services research. BMJ 1995; 311(6996): 42-5.
Temple-Smith M, Stoove M, Smith A, O'Brien M, Mitchell D, Banwell C, et al. Gender differences in seeking care for hepatitis C in Australia. J Subst Use 2007; 12(1): 59-70.
Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: A systematic review. Liver Int 2014; 34(10): 1452-63.
Mendes-Correa MC, Martins LG, Ferreira PA, Tenore S, Leite OH, Leite AG, et al. Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil. Braz J Infect Dis 2010; 14(3): 237-41.
Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93(1-2): 141-7.
Cooper CL, Giordano C, Mackie D, Mills EJ. Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Ther Clin Risk Manag 2010; 6: 207-12.
Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: A multi-city, mixed-methods study. Harm Reduct J 2014; 11: 1.
Chan KY, Reidpath DD. Stigmatization of patients with AIDS: Understanding the interrelationships between Thai nurses' attitudes toward HIV/AIDS, drug use, and commercial sex. AIDS Patient Care STDS 2007; 21(10): 763-75.
Alammehrjerdi Z, Massah O, Farhoudian A, Shishehgar S, Moradi A, Dolan K. Opioid use among women on a stable methadone dose. Iran J Psychiatry Behav Sci 2017; 1(3): e9867.
Coupland H, Day C, Levy MT, Maher L. Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users. Health Promot J Austr 2009; 20(3): 234-40.
National AIDS Committee Secretariat, Ministry of Health and Medical Education. Islamic Republic of Iran: AIDS Progress Report: On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS [Online]. [cited 2015]; Available from: URL: http://www.unaids.org/sites/default/files/country/documents/IRN_narrative_report_2015.pdf
Rezaei F, Noroozi A, Armoon B, Farhoudian A, Massah O, Sharifi H, et al. Social determinants and hepatitis C among people who inject drugs in Kermanshah, Iran: Socioeconomic status, homelessness, and sufficient syringe coverage. J Subst Use 2017; 22(5): 474-8.
Samiei M, Moradi A, Noori R, Aryanfard S, Rafiey H, Naranjiha H. Persian at-risk women and barriers to receiving HIV services in drug treatment: First report from Iran. Int J High Risk Behav Addict 2016; 5(2): e27488.